Incyte Corporation

Incyte Corporation (INCY)

$62.58

-0.29

(-0.46%)

Market is closed - opens 7 PM, 30 May 2023

Performance

  • $62.34
    $62.88
    $62.58
    downward going graph

    0.38%

    Downside

    Day's Volatility :0.86%

    Upside

    0.48%

    downward going graph
  • $62.32
    $86.29
    $62.58
    downward going graph

    0.42%

    Downside

    52 Weeks Volatility :27.78%

    Upside

    27.48%

    downward going graph

Returns

PeriodIncyte Corporation
3 Months
-18.23%
6 Months
-19.51%
1 Year
-17.45%
3 Years
-37.7%

Highlights

Market Capitalization
14.0B
Book Value
$20.01
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
1.43
PE Ratio
43.97
PEG Ratio
0.47
Wall Street Target Price
82.24
Profit Margin
9.35%
Operating Margin TTM
14.47%
Return On Assets TTM
5.78%
Return On Equity TTM
7.79%
Revenue TTM
3.5B
Revenue Per Share TTM
15.6
Quarterly Revenue Growth YOY
10.299999999999999%
Gross Profit TTM
1.6B
EBITDA
575.7M
Diluted Eps TTM
1.43
Quarterly Earnings Growth YOY
-0.43
EPS Estimate Current Year
3.4
EPS Estimate Next Year
4.69
EPS Estimate Current Quarter
0.75
EPS Estimate Next Quarter
0.91

Analyst Recommendation

Buy
    55%Buy
    44%Hold
    0
    0%Sell
Based on 27 Wall street analysts offering stock ratings for Incyte Corporation(by analysts ranked 0 to 5 stars)
Based on 27 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
16
16
Hold
12
11
10
Sell
00
00
1

Analyst Forecast

What analysts predicted

Upside of 31.42%

Current $62.58
Target $82.24

Company Financials

FY17Y/Y Change
Revenue
1.5B
↑ 38.93%
Net Income
-313.1M
↓ 400.46%
Net Profit Margin
-20.38%
↓ 29.81%
FY18Y/Y Change
Revenue
1.9B
↑ 22.5%
Net Income
109.5M
↓ 134.97%
Net Profit Margin
5.82%
↑ 26.2%
FY19Y/Y Change
Revenue
2.2B
↑ 14.71%
Net Income
446.9M
↑ 308.16%
Net Profit Margin
20.7%
↑ 14.88%
FY20Y/Y Change
Revenue
2.7B
↑ 23.53%
Net Income
-295.7M
↓ 166.17%
Net Profit Margin
-11.09%
↓ 31.79%
FY21Y/Y Change
Revenue
3.0B
↑ 11.98%
Net Income
948.6M
↓ 420.79%
Net Profit Margin
31.76%
↑ 42.85%
FY22Y/Y Change
Revenue
3.4B
↑ 13.67%
Net Income
340.7M
↓ 64.09%
Net Profit Margin
10.04%
↓ 21.72%
Q4 FY21Q/Q Change
Revenue
862.9M
↑ 6.13%
Net Income
563.9M
↑ 210.25%
Net Profit Margin
65.35%
↑ 43.0%
Q1 FY22Q/Q Change
Revenue
733.2M
↓ 15.02%
Net Income
38.0M
↓ 93.26%
Net Profit Margin
5.18%
↓ 60.17%
Q2 FY22Q/Q Change
Revenue
911.4M
↑ 24.3%
Net Income
161.4M
↑ 324.91%
Net Profit Margin
17.71%
↑ 12.53%
Q3 FY22Q/Q Change
Revenue
823.3M
↓ 9.67%
Net Income
112.8M
↓ 30.14%
Net Profit Margin
13.7%
↓ 4.01%
Q4 FY22Q/Q Change
Revenue
926.7M
↑ 12.56%
Net Income
28.5M
↓ 74.76%
Net Profit Margin
3.07%
↓ 10.63%
Q1 FY23Q/Q Change
Revenue
17.9M
↓ 98.07%
Net Income
1000.0K
↓ 96.49%
Net Profit Margin
5.59%
↑ 2.52%
FY17Y/Y Change
Total Assets
2.3B
↑ 40.52%
Total Liabilities
672.0M
↓ 44.88%
FY18Y/Y Change
Total Assets
2.6B
↑ 14.9%
Total Liabilities
719.8M
↑ 7.12%
FY19Y/Y Change
Total Assets
3.4B
↑ 29.52%
Total Liabilities
828.3M
↑ 15.08%
FY20Y/Y Change
Total Assets
3.6B
↑ 3.92%
Total Liabilities
949.7M
↑ 14.64%
FY21Y/Y Change
Total Assets
4.9B
↑ 38.54%
Total Liabilities
1.2B
↑ 22.5%
FY22Y/Y Change
Total Assets
5.8B
↑ 18.4%
Total Liabilities
1.5B
↑ 26.43%
Q4 FY21Q/Q Change
Total Assets
4.9B
↑ 17.49%
Total Liabilities
1.2B
↑ 10.78%
Q1 FY22Q/Q Change
Total Assets
5.1B
↑ 2.45%
Total Liabilities
1.2B
↑ 2.39%
Q2 FY22Q/Q Change
Total Assets
5.3B
↑ 5.24%
Total Liabilities
1.2B
↑ 3.6%
Q3 FY22Q/Q Change
Total Assets
5.5B
↑ 3.59%
Total Liabilities
1.3B
↑ 4.02%
Q4 FY22Q/Q Change
Total Assets
5.8B
↑ 6.0%
Total Liabilities
1.5B
↑ 14.59%
Q1 FY23Q/Q Change
Total Assets
79.6M
↓ 98.64%
Total Liabilities
33.3M
↓ 97.74%
FY17Y/Y Change
Operating Cash Flow
-93.0M
↓ 130.51%
Investing Cash Flow
-350.0M
↑ 50.54%
Financing Cash Flow
690.2M
↑ 1076.86%
FY18Y/Y Change
Operating Cash Flow
336.2M
↓ 461.58%
Investing Cash Flow
-86.4M
↓ 75.31%
Financing Cash Flow
14.7M
↓ 97.88%
FY19Y/Y Change
Operating Cash Flow
710.7M
↑ 111.36%
Investing Cash Flow
-87.5M
↑ 1.19%
Financing Cash Flow
45.7M
↑ 211.87%
FY20Y/Y Change
Operating Cash Flow
-124.6M
↓ 117.53%
Investing Cash Flow
-269.0M
↑ 207.59%
Financing Cash Flow
71.7M
↑ 56.87%
FY21Y/Y Change
Operating Cash Flow
749.5M
↓ 701.52%
Investing Cash Flow
-207.7M
↓ 22.79%
Financing Cash Flow
6.2M
↓ 91.39%
FY22Y/Y Change
Operating Cash Flow
969.9M
↑ 29.41%
Investing Cash Flow
-78.5M
↓ 62.18%
Financing Cash Flow
-794.0K
↓ 112.86%
Q4 FY21Q/Q Change
Operating Cash Flow
115.4M
↓ 54.78%
Investing Cash Flow
-66.0M
↑ 101.65%
Financing Cash Flow
9.0M
↓ 146.55%
Q1 FY22Q/Q Change
Operating Cash Flow
215.7M
↑ 87.03%
Investing Cash Flow
-16.7M
↓ 74.64%
Financing Cash Flow
96.0K
↓ 98.93%
Q2 FY22Q/Q Change
Operating Cash Flow
174.2M
↓ 19.27%
Investing Cash Flow
-12.5M
↓ 25.48%
Financing Cash Flow
15.9M
↑ 16463.54%
Q3 FY22Q/Q Change
Operating Cash Flow
296.4M
↑ 70.18%
Investing Cash Flow
-28.4M
↑ 127.58%
Financing Cash Flow
-14.3M
↓ 190.0%
Q4 FY22Q/Q Change
Operating Cash Flow
283.7M
↓ 4.29%
Investing Cash Flow
-20.9M
↓ 26.37%
Financing Cash Flow
-2.5M
↓ 82.67%

Technicals Summary

Sell

Neutral

Buy

Incyte Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin

Institutional Holdings

  • Baker Bros Advisors LP

    16.22%
  • Vanguard Group Inc

    9.75%
  • BlackRock Inc

    8.89%
  • Dodge & Cox

    8.67%
  • Royal Bank of Canada

    4.23%
  • State Street Corporation

    4.18%

Company Information

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

Organization
Incyte Corporation
Employees
2324
CEO
Mr. Herve Hoppenot
Industry
Health Technology

FAQs